共查询到17条相似文献,搜索用时 624 毫秒
1.
[目的]探讨低、高级别卵巢浆液性癌中CA125、p53和Ki-67的表达及其与预后的相关性.[方法]依照两级分级系统对卵巢浆液性癌进行分级,分别选取低级别浆液性癌31例和高级别癌31例,观察其临床病理特点,并采用免疫组织化学SP法检测癌组织中CA125、p53和Ki-67的表达情况.[结果]低级别组p53阳性率显著低于高级别组(32.26% vs 74.19%,P<0.001),Ki-67阳性指数显著低于高级别组(29.03%vs80.65%,P<0.001);低级别组5年总生存率、无病生存率均优于高级别组(P<0.05).[结论]两级分级系统对卵巢浆液性癌的预后判断具有提示意义,CA125、p53和Ki-67在卵巢低、高级别浆液性癌中的表达差异有统计学意义. 相似文献
2.
3.
4.
目的探讨受体酪氨酸激酶EphB3蛋白在正常输卵管上皮组织、卵巢浆液性肿瘤组织和卵巢浆液性癌组织中的表达及其与卵巢浆液性癌临床病理特征的关系。方法采用免疫组化法检测9例正常输卵管、12例卵巢浆液性囊腺瘤和53例卵巢浆液性癌组织中EphB3蛋白的表达情况,进一步分析EphB3蛋白表达与卵巢癌临床病理特征的关系。结果正常输卵管上皮和卵巢良性肿瘤中EphB3蛋白的强阳性(+++)表达率分别为100.0%(9/9)、75.0%(9/12),明显高于卵巢浆液性癌的18.9%(10/53),差异有统计学意义(P<0.001)。EphB3蛋白表达与肿瘤分级(r=-0.606,P<0.001)和FIGO分期(r=-0.463,P<0.001)呈负相关,而与患者年龄、大网膜转移、腹腔转移和盆腔淋巴结转移无关(P>0.05)。结论 EphB3可能成为区分高、低级别浆液性癌的辅助指标,帮助卵巢浆液性癌病理诊断及制定治疗方案。 相似文献
5.
目的:探讨卵巢浆液性肿瘤组织中p16、p53、BRAF、Bcl-2的表达及临床意义。方法:收集宁夏医科大学总医院病理科2017年至2018年确诊的卵巢浆液性肿瘤136例,其中浆液性囊腺瘤52例,交界性囊腺瘤22例,低级别浆液性癌18例,高级别浆液性癌44例;另收集卵巢良性肿瘤和卵巢癌手术切除标本各30例。分别采用免疫组织化学SP法检测p16、p53、BRAF、Bcl-2的表达,实时定量PCR法检测p16、p53在卵巢良恶性肿瘤组织中的表达。结果:卵巢浆液性囊腺瘤、交界性囊腺瘤、低/高级别浆液性癌组织中p16的阳性率分别为3.8%、45.5%、88.9%、81.8%,p53为0、9.1%、55.6%、45.5%,BRAF为46.2%、45.5%、22.2%、31.8%,Bcl-2为46.2%、45.5%、38.9%、47.7%。不同类型浆液性肿瘤组织中p16、p53表达均有显著性差异(P<0.001),但BRAF、Bcl-2表达未见明显差异。与卵巢良性肿瘤相比,p16在交界性肿瘤、卵巢癌中的阳性表达明显升高,差异有显著统计学意义(P<0.012 5);p53在卵巢癌中的阳性表达明显高于良性肿瘤(P<0.001);p16和p53的表达呈正相关(P<0.05)。p53、Bcl-2与卵巢癌淋巴结转移有相关性(P<0.001),p16、p53、Bcl-2与盆腔侵犯有关(P<0.05),p53、BRAF、Bcl-2与CA125表达有不同程度相关性(P<0.05)。p16、p53联合检测对卵巢癌诊断的敏感性和特异性为90.0%、76.7%。结论:p16、p53、BRAF、Bcl-2参与卵巢癌的发生发展,p16和p53基因突变可能在卵巢浆液性肿瘤的恶性进展中发挥作用,联合检测p16、p53对卵巢癌诊断有指示意义。 相似文献
6.
目的探讨抑癌基因P53在中晚期肝细胞癌中的表达及其预后价值。方法应用免疫组化法(LSAB法)检测P53在45例肝癌组织中表达。结果P53在肝癌细胞中的阳性表达率为44.4%(20/45),癌旁组织无表达;P53在肝癌细胞高中分化组中阳性率为34.3%(12/35),而低分化组中为80%(8/10),两者差异显著(P<0.05);肝癌术后生存期≤1年组中P53阳性率为65%(11/17),而>1年组为32%(9/28),两者差异显著(P<0.05)。结论抑癌基因P53的突变是部分肝细胞癌变原因之一,且P53的检测可为临床评价肝癌细胞分化程度和患者的预后提供客观参考 相似文献
7.
8.
WT1与P53在卵巢浆液性癌中的表达及意义 总被引:1,自引:0,他引:1
目的 检测WT1和P53在卵巢浆液性肿瘤中的表达,探讨其临床病理学意义及二者的关系.方法 采用免疫组化Envision二步法检测在卵巢良性浆液性肿瘤、交界性浆液性肿瘤和浆液性癌各40例中的WT1和P65表达情况,分析其表达水平与卵巢浆液性癌中临床病理特征的关系.结果 WT1在卵巢良性浆液性肿瘤、交界性肿瘤和浆液性癌中阳... 相似文献
9.
目的:探讨检测点激酶2(check point kinase2,Chk2)和重构剪切因子1(remodeling and spacing factor1,Rsf1)在卵巢浆液性腺癌(ovarian serous adenocarcinoma,OSA)中表达及其临床意义。方法:采用免疫组化SP法检测58例高级别OSA、14例低级别OSA中Chk2和Rsf1蛋白的表达水平,分析与临床病理参数的关系。并检测27例卵巢交界性浆液性肿瘤(ovarian borderline serous tumor,OBST)中两种蛋白的表达水平,与OSA进行对比分析。结果:Chk2在高级别和低级别OSA中阳性率分别为79.3%(46/58)和50.0%(7/14),差异有统计学意义,χ2=4.99,P=0.026;在OSA和OBST中阳性率分别为77.8%(56/72)和44.4%(12/27),差异有统计学意义,χ2=7.41,P=0.006。Chk2的表达与OSA复发及3年生存期有相关性,P<0.05;而与年龄、肿瘤最大径、淋巴结有无转移、发病部位及pTNM分期无关,P>0.05。Rsf1在高级别和低级别OSA中阳性率分别为86.2%(50/58)和57.1%(8/14),差异有统计学意义,χ2=6.08,P=0.023;在OSA及OBST中阳性率分别为79.2%(57/72)和51.9%(14/27),差异有统计学意义,χ2=8.16,P=0.004。Rsf1的表达与OSA复发及pTNM分期有相关性,P<0.05;而与年龄、肿瘤大小、淋巴结有无转移、发病部位及3年生存期无关,P>0.05。Chk2和Rsf1的表达存在明显相关性,r=0.343,P=0.003。结论:Chk2与Rsf1在OSA的发生发展中起重要作用,可作为临床指导治疗和评价患者预后的重要标志。 相似文献
10.
目的 :研究肿瘤组织癌相关基因P53、Rb、P16、和P21表达水平的临床意义。 方法:用流式细胞仪(FCM)检测30例卵巢癌和乳腺癌瘤体中心灶P53、Rb、P16、和P21异常表达的阳性细胞百分率。 结果: 卵巢癌和乳腺癌的P53、Rb、P16、和P21基因蛋白表达水平及异常表达率均无明显差异(P>0.05)。30例肿瘤的4种基因异常表达率分别为 :P5340 % ;Rb53.3 % ;P2166.7 %和P1653.3 %。96.7 %(29/30)的肿瘤存在至少一种以上癌相关基因的异常表达。异常表达两个以上癌相关基因的患者较易出现临床转移。 结论:联合检测实体肿瘤P53、Rb、P16、和P21基因蛋白表达水平并综合分析这些指标 ,有助于识别肿瘤不同的生物学特性和准确判断患者预后 相似文献
11.
Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. 总被引:4,自引:0,他引:4
Chih-Yi Hsu Robert Bristow Moon Seok Cha Brant G Wang Chung-Liang Ho Robert J Kurman Tian-Li Wang Ie-Ming Shih 《Clinical cancer research》2004,10(19):6432-6436
PURPOSE: Mitogen-activated protein kinase (MAPK) plays a pivotal role in signal transduction. Activation of MAPK is regulated by upstream kinases including KRAS and BRAF, which are frequently mutated in low-grade ovarian serous carcinoma. This study evaluates the expression of active MAPK in ovarian serous carcinomas, with response to treatment and survival. EXPERIMENTAL DESIGN: Expression of active MAPK was assessed by immunohistochemistry in 207 cases of ovarian serous tumors. Immunoreactivity was correlated with tumor grade, mutational status of KRAS and BRAF, in vitro drug resistance, and clinical outcome. RESULT: There was a lower frequency of expression of active MAPK in high-grade ovarian serous carcinomas as compared with low-grade serous tumors, including borderline tumors and low-grade serous carcinoma (P < 0.001). Active MAPK was present in all of the 19 low-grade tumors with either KRAS or BRAF mutations as well as in 14 (41%) of 34 tumors with wild-type KRAS and BRAF in both low- and high-grade carcinomas. Expression of active MAPK alone served as a good survival indicator in the 2-year follow-up (P = 0.037) but not in the 5-year follow-up (P = 0.145). However, a combination of expression of active MAPK and in vitro sensitivity of paclitaxel significantly correlated with a better prognosis in 5-year survival rate (P = 0.048) in patients with advanced-stage high-grade serous carcinoma. CONCLUSIONS: Active MAPK is more frequently expressed in low-grade than in high-grade ovarian serous carcinoma. Active MAPK serves as a good prognostic marker in patients with high-grade serous carcinomas. 相似文献
12.
13.
PTEN和P53蛋白在子宫内膜癌中的表达及临床意义 总被引:1,自引:0,他引:1
目的:探讨PTEN和P53蛋白在子宫内膜癌中的表达及临床意义。方法:采用免疫组织化学S-P法检测42例子宫内膜癌、28例子宫内膜增殖症和20例正常增生期子宫内膜组织中PTEN和P53蛋白的表达。结果:与增生期子宫内膜100%表达率相比,PTEN蛋白子宫内膜非典型增生及子宫内膜癌中的阳性表达率逐渐降低,分别为66.7%和53.1%。随着子宫内膜癌临床分期的升高、病理分级的降低及肌层浸润的加深,PTEN蛋白的表达呈逐渐降低的趋势。子宫内膜癌组织中PTEN蛋白的失表达主要局限于子宫内膜样腺癌,占46.9%,10例子宫内膜浆液性腺癌中则未见PTEN的失表达,PTEN失表达在这两组肿瘤间的差异有统计学意义(P=0.001)。P53蛋白过表达在子宫内膜样腺癌中占25%,在子宫内膜浆液性腺癌中为80%,两组间差异有统计学意义(P=0.001)。结论:PTEN的缺失和P53过表达与子宫内膜癌的发生、发展有关,同时预示着子宫内膜癌的不良预后。 相似文献
14.
研究TGFBI基因启动子甲基化与CyclinD1蛋白表达在卵巢上皮性癌组织中关系,探讨TGFBI基因启动子甲基化在卵巢上皮性癌形成过程中的影响及意义。方法:用甲基化PCR的方法对20例正常卵巢上皮性组织(A组),20例良性卵巢上皮性肿瘤组织(B组),30例卵巢上皮性癌组织(C组)中TGFBI基因启动子甲基化进行检测,用免疫组化SP方法检测上述标本中CyclinD1蛋白的表达的情况。结果:1)C组TGFBI基因启动子甲基化频率高于B组及A组(P<0.05);2)CyclinD1蛋白在卵巢上皮组织中的表达为:C组>B组>A组,各组之间差异均有统计学意义(P<0.016 7);3)卵巢上皮性癌组织中CyclinD1蛋白表达增高与TGFBI基因启动子发生甲基化有关(r=0.505,P<0.05)。结论:TGFBI基因DNA启动子发生甲基化可能上调CyclinD1蛋白的表达,刺激细胞异常增殖。该机制可能参与卵巢上皮性癌的发生发展。 相似文献
15.
Expression of c-ABL,c-KIT,and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium 总被引:4,自引:0,他引:4
Schmandt RE Broaddus R Lu KH Shvartsman H Thornton A Malpica A Sun C Bodurka DC Gershenson DM 《Cancer》2003,98(4):758-764
BACKGROUND: Tyrosine kinases, such as c-KIT, c-ABL, and platelet-derived growth factor-beta (PDGFR-beta), are important regulators of cell growth. Highly potent and selective inhibitors of tyrosine kinases are being investigated as alternatives to standard chemotherapy. One such inhibitor, imatinib mesylate, is being used to treat gastrointestinal stromal tumors and chronic myelogenous leukemia. Ovarian carcinomas frequently develop resistance to conventional chemotherapeutic agents. Immunohistochemical expression of c-ABL, PDGFR-beta, and c-KIT was evaluated in ovarian carcinomas to determine whether treatment with imatinib mesylate might be feasible. METHODS: The expression of c-ABL, c-KIT, and PDGFR-beta in tumors was evaluated by immunohistochemical analysis of 52 ovarian serous carcinomas, including 21 low-grade (well differentiated) and 31 high-grade (poorly differentiated) tumors. Fourteen normal ovaries were also evaluated. RESULTS: In normal ovarian surface epithelium, c-ABL was expressed universally. PDGFR-beta was expressed in the majority (93%) of samples of normal ovarian epithelium, whereas the c-KIT protein was undetectable in normal ovarian surface epithelium. Overall, c-ABL was expressed in 71% of serous carcinomas. c-ABL was expressed more frequently in the low-grade serous carcinomas (81%) compared with the high-grade serous carcinomas (65%). PDGFR-beta expression was observed in 81% of serous carcinomas overall and was observed more frequently in higher-grade tumors. c-KIT immunohistochemical staining was absent in low-grade tumors but was present in 26% of high-grade serous carcinomas. CONCLUSIONS: The majority of ovarian serous carcinomas express one or more of the kinases targeted by the tyrosine kinase inhibitor, imatinib mesylate, suggesting the potential usefulness of this drug in the treatment of ovarian carcinoma. 相似文献
16.
17.